Diamond Hill Capital's BSX Position Overview
Diamond Hill Capital (via Diamond Hill Capital Management INC) currently holds 250,214 shares of Boston Scientific Corporation (BSX) worth $23.86 M, representing 0.12% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Diamond Hill Capital has maintained a long-term strategic position in BSX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2014, adding 1.52 M shares. Largest reduction occurred in Q2 2016, reducing 15.48 M shares.
Analysis based on 13F filings available since 2013 Q2
Diamond Hill Capital's Boston Scientific Corporation (BSX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Boston Scientific Corporation (BSX) Trades by Diamond Hill Capital
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -27,857 | Reduce 10.02% | 250,214 | $95.35 |
| Q3 2025 | -53,200 | Reduce 16.06% | 278,071 | $97.63 |
| Q2 2025 | -61,108 | Reduce 15.57% | 331,271 | $107.41 |
| Q1 2025 | -81,317 | Reduce 17.17% | 392,379 | $100.88 |
| Q4 2024 | -16,225 | Reduce 3.31% | 473,696 | $89.32 |
| Q3 2024 | -4,644 | Reduce 0.94% | 489,921 | $83.80 |
| Q2 2024 | -38,145 | Reduce 7.16% | 494,565 | $77.01 |
| Q1 2024 | -143,384 | Reduce 21.21% | 532,710 | $68.49 |
| Q4 2023 | -31,741 | Reduce 4.48% | 676,094 | $57.81 |
| Q3 2023 | -21,015 | Reduce 2.88% | 707,835 | $52.80 |
| Q2 2023 | -20,709 | Reduce 2.76% | 728,850 | $54.09 |
| Q1 2023 | -14,004 | Reduce 1.83% | 749,559 | $50.03 |
| Q4 2022 | -6,488 | Reduce 0.84% | 763,563 | $46.27 |
| Q3 2022 | -4,976 | Reduce 0.64% | 770,051 | $38.73 |
| Q2 2022 | +3,277 | Add 0.42% | 775,027 | $37.27 |
| Q1 2022 | -164,995 | Reduce 17.61% | 771,750 | $44.29 |
| Q4 2021 | -31,098 | Reduce 3.21% | 936,745 | $42.48 |
| Q3 2021 | -128,849 | Reduce 11.75% | 967,843 | $43.39 |
| Q2 2021 | -108,112 | Reduce 8.97% | 1.1 M | $42.76 |
| Q1 2021 | -25,391 | Reduce 2.06% | 1.2 M | $38.65 |
| Q4 2020 | +65,294 | Add 5.61% | 1.23 M | $35.95 |
| Q3 2020 | -497,065 | Reduce 29.91% | 1.16 M | $38.21 |
| Q2 2020 | -377,801 | Reduce 18.52% | 1.66 M | $35.11 |
| Q1 2020 | +180,648 | Add 9.72% | 2.04 M | $32.63 |
| Q4 2019 | -141,828 | Reduce 7.09% | 1.86 M | $45.22 |
| Q3 2019 | -5,167 | Reduce 0.26% | 2 M | $40.69 |
| Q2 2019 | +69,262 | Add 3.58% | 2.01 M | $42.98 |
| Q1 2019 | -352,753 | Reduce 15.41% | 1.94 M | $38.38 |
| Q4 2018 | -622,930 | Reduce 21.39% | 2.29 M | $35.34 |
| Q3 2018 | -46 | Reduce 0.00% | 2.91 M | $38.50 |
| Q2 2018 | -86,813 | Reduce 2.89% | 2.91 M | $32.70 |
| Q1 2018 | -24,810 | Reduce 0.82% | 3 M | $27.32 |
| Q4 2017 | +14,311 | Add 0.48% | 3.02 M | $24.79 |
| Q3 2017 | -3,721 | Reduce 0.12% | 3.01 M | $29.17 |
| Q2 2017 | -347,644 | Reduce 10.34% | 3.01 M | $27.72 |
| Q1 2017 | +9,850 | Add 0.29% | 3.36 M | $24.87 |
| Q4 2016 | +61,546 | Add 1.87% | 3.35 M | $21.63 |
| Q3 2016 | -1.57 M | Reduce 32.36% | 3.29 M | $23.80 |
| Q2 2016 | -15.48 M | Reduce 76.09% | 4.86 M | $23.37 |
| Q1 2016 | +739,511 | Add 3.77% | 20.34 M | $18.81 |
| Q4 2015 | -1.13 M | Reduce 5.43% | 19.6 M | $18.44 |
| Q3 2015 | +507,816 | Add 2.51% | 20.72 M | $16.41 |
| Q2 2015 | -210,112 | Reduce 1.03% | 20.22 M | $17.70 |
| Q1 2015 | -2.92 M | Reduce 12.51% | 20.43 M | $17.75 |
| Q4 2014 | +210,361 | Add 0.91% | 23.35 M | $13.25 |
| Q3 2014 | +1.52 M | Add 7.04% | 23.14 M | $11.81 |
| Q2 2014 | +571,830 | Add 2.72% | 21.62 M | $12.77 |
| Q1 2014 | +8,896 | Add 0.04% | 21.04 M | $13.52 |
| Q4 2013 | +364,747 | Add 1.76% | 21.03 M | $12.02 |
| Q3 2013 | +203,847 | Add 1.00% | 20.67 M | $11.74 |
| Q2 2013 | +20.47 M | Add 0.00% | 20.47 M | $9.27 |
Diamond Hill Capital's Boston Scientific Corporation Investment FAQs
Diamond Hill Capital first purchased Boston Scientific Corporation (BSX) in Q2 2013, acquiring 20,465,802 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Diamond Hill Capital has held Boston Scientific Corporation (BSX) for 51 quarters since Q2 2013.
Diamond Hill Capital's largest addition to Boston Scientific Corporation (BSX) was in Q2 2013, adding 20,465,802 shares worth $189.72 M.
According to the latest 13F filing for Q4 2025, Diamond Hill Capital's firm, Diamond Hill Capital Management INC, owns 250,214 shares of Boston Scientific Corporation (BSX), valued at approximately $23.86 M.
As of the Q4 2025 filing, Boston Scientific Corporation (BSX) represents approximately 0.12% of Diamond Hill Capital's publicly disclosed stock portfolio, making it one of their key holdings.
Diamond Hill Capital's peak holding in Boston Scientific Corporation (BSX) was 23,348,194 shares, as reported at the end of Q4 2014.